Figures computed from official regulatory filings — .
Ownershipinsiders 47.08% · institutions 0% · short 0.1% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Emmaus Life Sciences, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. It has a license agreement with Kainos Medicine, Inc., which includes the patent rights of IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, such as leukemia, lymphoma, and solid tumor cancers. Emmaus Life Sciences, Inc. was founded in 2000 and is headquartered in Torrance, California.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
414 buys2 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| LEE WILLIS Ctrack record | Buy | $1.4K | conv 52First in 12mo |
| SEC |
| LEE WILLIS Ctrack record | Buy | $1.8K | conv 37 | SEC |
| LEE WILLIS Ctrack record | Buy | $5.7K | conv 41 | SEC |
| LEE WILLIS Ctrack record | Buy | $5K | conv 39 | SEC |
| LEE WILLIS Ctrack record | Buy | $1.7K | conv 66 | SEC |
| LEE WILLIS Ctrack record | Buy | $2.5K | conv 31 | SEC |
| Lim Seah H.track record | Buy | $800 | conv 44First in 12mo | SEC |
| LEE WILLIS Ctrack record | Buy | $1.3K | conv 26 | SEC |
| LEE WILLIS Ctrack record | Buy | $10K | conv 70 | SEC |
| LEE WILLIS Ctrack record | Buy | $1.6K | conv 30 | SEC |
| LEE WILLIS Ctrack record | Buy | $1.8K | conv 39 | SEC |
| ZEN Wei Peutrack record | AwardD (derivative) | $15K | SEC |
| Lim Seah H.track record | AwardD (derivative) | $15K | SEC |
| Stark Charles William | AwardD (derivative) | $30K | SEC |
| NAGASAKI YASUSHI | AwardD (derivative) | $30K | SEC |
| Sekulich George | AwardD (derivative) | $30K | SEC |
| Zwicker Ian Harvey | AwardD (derivative) | $15K | SEC |
| LEE WILLIS Ctrack record | AwardD (derivative) | $30K | SEC |
| LEE WILLIS Ctrack record | Buy | $1.4K | conv 42 | SEC |
| LEE WILLIS Ctrack record | Buy | $4.3K | conv 39 | SEC |
| LEE WILLIS Ctrack record | Buy | $132 | conv 36 | SEC |
| LEE WILLIS Ctrack record | Buy | $1.4K | conv 34 | SEC |
| LEE WILLIS Ctrack record | Buy | $7.1K | conv 46 | SEC |
| LEE WILLIS Ctrack record | Buy | $900 | conv 38 | SEC |
| Lim Seah H.track record | Sell | $1.6K | SEC |